Fighting Cancer with NanoTherm® therapy

MagForce has successfully moved forward on its path to develop NanoTherm® therapy into a valued treatment for brain and prostate cancer.

We have five NanoActivator® devices in operation in world-class German hospitals, and additional centers are trained to perform the instillation of the nanoparticles. Commercial treatments have now re started, and patients from all over the world can benefit from our unique technology.

Additionally, in the US, the U.S. Food and Drug Administration (FDA) has granted our US subsidiary MagForce USA, Inc. the Investigational Device Exemption (IDE) to conduct a clinical trial with NanoTherm® therapy as focal ablation treatment for intermediate risk prostate cancer. The approval of this IDE now allows MagForce to conduct a pivotal clinical evaluation with our innovative therapy at selected medical centers in the US.



Compliant with European Standard